FDA Approves Arvinas and Pfizer’s VEPPANU for Advanced Breast Cancer Treatment

Arvinas and Pfizer have secured U.S. FDA approval for VEPPANU (vepdegestrant), marking it as the first-ever approved PROTAC protein degrader for advanced breast cancer treatment. This landmark approval arrived well ahead of its 2026 PDUFA date, specifically targeting patients with ESR1 mutations. Adding to the sector's momentum, Celcuity recently announced that its Phase 3 VIKTORIA-1 trial achieved its primary endpoint for the PIK3CA mutant cohort. Detailed data from Celcuity’s trial is scheduled for presentation at the 2026 ASCO Annual Meeting. These concurrent breakthroughs highlight a significant shift toward targeted oncology therapies addressing treatment resistance. Analysts expect these clinical successes to serve as major catalysts for valuation across the biotechnology and pharmaceutical landscapes.